Biogen stock climbs as investors shrug off analyst skepticism about Alzheimer’s drug

admin 4 years ago No Comments

This post was originally published on this site

Shares of Biogen rose 4.5% in afternoon trading in response to new data that indicates its recently resurrected experimental Alzheimer’s disease treatment can reduce cognitive decline.

Prev Article Next Article

Dow Jones Newswires: Tencent-backed Tuhu Car plans Hong Kong IPO

admin September 14, 2023

Help My Career: The ‘best job in America’ pays over $120,000 a year — and offers a low-stress, healthy work-life balance

admin January 11, 2023

NewsWatch: Nasdaq 15,000 is near. Do I hear 30,000?

admin August 1, 2021

Market Extra: Will Thursday’s inflation data kill the stock-market bounce? Here’s what investors want to see

admin February 9, 2022

Realtor.com: After Selling His Mod Home, Will Arnett Snags $16.4M Modern Farmhouse

admin September 1, 2021

The Conversation: This new study shows how well a coronavirus vaccine must work before we can stop social distancing

admin July 15, 2020

Biogen stock climbs as investors shrug off analyst skepticism about Alzheimer’s drug

About The Author

admin

Add Comment

Email

Related Posts

About The Author

admin

Add Comment